Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
616 hedge funds and large institutions have $16.1B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2022 Q2 according to their latest regulatory filings, with 86 funds opening new positions, 246 increasing their positions, 208 reducing their positions, and 78 closing their positions.
124% more call options, than puts
Call options by funds: $91.2M | Put options by funds: $40.8M
18% more repeat investments, than reductions
Existing positions increased: 246 | Existing positions reduced: 208
10% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 78
1% less funds holding
Funds holding: 620 → 616 (-4)
4% less funds holding in top 10
Funds holding in top 10: 27 → 26 (-1)
25% less capital invested
Capital invested by funds: $21.5B → $16.1B (-$5.37B)
Top Buyers
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$118M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$104M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$86.5M |
| 4 |
BlackRock
New York
|
+$72.2M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$68.7M |
Top Sellers
HZNP Hedge Fund Activity: Q2 2022 in Review
616 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q2 2022, worth a combined $16.1B — down 25% from $21.5B a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new HZNP positions and 78 closed out — a net gain of 8 holders — while 246 added to existing stakes and 208 trimmed.
The largest buyer was Ameriprise, adding an estimated $118M. The largest seller was Fidelity Investments, cutting an estimated $287M.
- 616 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q2 2022, down from 620 in Q1 2022.
- Funds reported $16.1B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q2 2022, down 25% quarter-over-quarter.
- 86 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q2 2022 and 78 closed out, a net change of +8 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q2 2022 was Ameriprise, an estimated $118M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q2 2022 was Fidelity Investments, an estimated $287M sold.
Based on aggregated 13F filings for Q2 2022.